< Brochure Homepage | Faculty Index | Pathology Homepage



Email dchan@jhmi.edu
Phone (410) 955-2674

Daniel W. Chan, Ph.D., DABCC, FACB

Professor of Pathology, Oncology, Radiology and Urology
Director, Clinical Chemistry Division
Co-Director of Pathology Core Laboratories
Director, Center for Biomarker Discovery and Translation


The focus of my research is cancer proteomics. In 2000, I founded the Center for Biomarker Discovery and Translation. The focus of the Center is to discover and translate proteomics cancer biomarkers using mass spectrometry, protein microarrays and immunoassays. Our team developed the test OVA1 which is based on 5 proteomic biomarkers for ovarian cancer. In 2009, this test became the 1st FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). I am the principal investigator (PI) of the Biomarker Reference Laboratory (BRL) for the National Cancer Institute (NCI) Early Detection Research Network (EDRN) and the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). We were instrumental in the development of public-private partnerships leading to the clinical study, publication and FDA approval in 2012 of two new prostate cancer tests - proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc). I was one of founders of the USHUPO (Human Proteomics Organization) society. Currently, I am the Editor-in-Chief of Clinical Proteomics. At this year's HUPO world congress in Madrid, Spain, my research was recognized and awarded the inaugural "Translational Proteomics Award" for outstanding achievement in proteomics.

Publications
Füzéry AK, Levin J, Chan MM and Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013, 10:13.

Sartori DA and Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol 2014, 26(3): 259-64.

Li, D and Chan DW. Proteomic cancer biomarkers from discovery to approval: it's worth the effort. Expert Rev Proteomics 2014, 11(2):135-6.

Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. Theranostics. 2015 Jan 1;5(3):267-76



 


Copyright © 2017 Johns Hopkins University. All Rights Reserved